Research programme: prodrug therapeutics - Ascendis Pharma

Drug Profile

Research programme: prodrug therapeutics - Ascendis Pharma

Alternative Names: Transcon CNP; TransCon Hydrogel GLP-1; TransCon Hydrogel insulin; TransCon Hydrogel paliperidone; TransCon Hydrogel pramipexole; TransCon PEG interferon α

Latest Information Update: 02 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ascendis Pharma
  • Class Benzothiazoles; Glucagon-like peptides; Insulins; Interferons; Isoxazoles; Polyethylene glycols
  • Mechanism of Action C-type natriuretic peptide modulators; Dopamine D2 receptor agonists; Dopamine D2 receptor antagonists; Dopamine D3 receptor agonists; Dopamine D4 receptor agonists; Glucagon like peptide 1 receptor agonists; Insulin receptor agonists; Interferon alpha stimulants; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Achondroplasia; CNS disorders; Diabetes mellitus; Hepatitis C

Most Recent Events

  • 03 Apr 2017 Ascendis Pharma plans a phase I trial for Hypoparathyroidism in 2017
  • 01 Apr 2017 Pharmacodynamics, pharmacokinetics, and safety data from preclinical studies in Achondroplasia presented at the 99th Annual Meeting of the Endocrine Society (ENDO-2017)
  • 31 Aug 2016 Preclinical trials in Achondroplasia in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top